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Should women who come from at-risk families get life insur-
ance before being tested for genetic susceptibility to breast
cancer? Should physicians warn patients who request a genetic
test to get life insurance first? How should physicians react to
requests from insurance companies for genetic information
about their patients?
There are no definitive answers to questions suchas these. However, a 2003 public opinion survey1revealed that the wide majority of Canadians re-
ject the idea that insurance companies have the right to
ask for genetic information even if applicants have per-
sonal knowledge of this information. Indeed, the interna-
tional debate surrounding the role of life insurance, the
necessity of risk rating and the notion of “acceptable dis-
crimination” has raised questions about the larger social
role of insurance. This debate has been polarized by re-
cent developments in the field of genetics that, in theory,
would allow insurers to make use of genetic testing tech-
nology as a new underwriting tool.
The importance of genetic information has grown expo-
nentially in the last 20 years. Since the Law Reform Com-
mission of Canada first raised the issue of “insurance test-
ing” in 1991, scientists have completed a draft of the
human genome and have identified more than 2 million
single nucleotide polymorphisms.2 The number of predic-
tive genetic tests offered for monogenic and complex (mul-
tifactorial) diseases has multiplied. Nevertheless, only a
small portion of the therapeutic possibilities offered by ge-
netics has been realized.
In the United States, the genetics and insurance de-
bate has focused predominantly on access to health insur-
ance. Canada, like most European countries, has a uni-
versal health care system, and thus the focus of discussion
has been on access to life insurance as a basic socioeco-
nomic good. In Europe, the Convention on Human
Rights and Biomedicine (the “Oveido Convention”) rati-
fied by 17 countries unambiguously states that genetic
testing can be used only for health reasons and for re-
search.3 In contrast to the large number of European
countries that have clarified their positions regarding the
future of genetics and life insurance (see the online table
at www.cmaj.ca/cgi/content/full/170/9/1421/DC1),
Canada has yet to take a position. Any initiative in this
regard should be based on an understanding of how life
insurance works, the nature of genetic information, the
history of the debate on genetics and life insurance in
Canada and the reasons why a Canadian task force de-
cided to take up the challenge.
Life insurance
Life insurance should be distinguished from social secu-
rity, disability insurance, unemployment insurance, the
Canadian Pension Plan and the principle of universality
underlying Canada’s health care system. Life insurance is a
private contract between the policy-holder and the insurer.
Its principal role is to provide income security to the bene-
ficiary in the event of the insured’s death.
To calculate the amount of the premium, the insurer
uses information such as age, sex, health status and lifestyle
as well as some information on the medical history of the
insured’s family. According to the principle of mutuality
underlying insurance, an insured person will then be as-
signed to a group with similar risk factors. By its very na-
ture, the process of underwriting discriminates between in-
dividuals4 to pool them into at-risk groups.5,6 Unbeknownst
to most, 90% of life insurance applicants are insured at
standard rates.7
Is genetic information different from medical
information?
Genetic information may alter one’s perception of fu-
ture medical risk. It can affect choices regarding the pur-
chase of life insurance and the premiums to be paid.8 Be-
cause of the sensitive, personal, familial and social nature
of genetic information, its confidentiality is essential.8 At
the same time, we must recognize that these characteris-
tics also apply to other types of information about med-
ical risk (e.g., blood pressure, communicable diseases).9
However, knowledge of genetic information will permit
individuals (and insurance companies) to quantify their
own risk with much greater accuracy. For insurance com-
panies, this will mean even greater stratification of risk
(risk spreading) and greater variability in premiums
charged. Although genetic information may in reality
not be different from any other type of actuarial “med-
ical” information, the public perceives genetic informa-
tion as different.1 This fact cannot be discounted or 
dismissed.
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Insurance and genetics in Canada: 
historical overview
The relation between genetics and life insurance be-
came an issue in Canada in 1990 when a Quebec resi-
dent’s claim for her husband’s life insurance was denied
by their insurance company. The company argued that
the husband had withheld genetic information. The appli-
cant, like other members of his family, had myotonic dys-
trophy, a genetic disease with variable expression. Having
no outward signs of this condition, he answered “No” to
the question, “Do you have any anomalies?” The Quebec
Superior Court ruled in favour of the insurance
company.10
Shortly following that incident, the Law Reform Com-
mission of Canada released the study paper “Human dig-
nity and genetic heritage” and suggested that “a basic ... life
insurance for all applicants with ‘no questions asked’ could
provide minimum coverage to everyone and avoid prob-
lems of discrimination. Additional coverage could be de-
pendent on an agreement by the applicant to be tested for
genetic disorders.”11
This was followed in 1996 by the Ontario Law Reform
Commission’s “Report on genetic testing.”12 This report
maintained that:
Insurability is not a trait but a concept of membership. It ex-
presses the criteria used by a group to decide whom to include
and exclude from its redistributive system. Treated as a scientific
test about individuals, [i]t disguises fundamentally political deci-
sions about membership in a community of mutual responsibil-
ity. This issue can be answered only to the extent that the guar-
antee of a minimum level of insurance in these circumstances
can be justified by a collective agreement to accept the diversity,
and concomitant expense, of our genetic heritage out of respect
for the principles of solidarity and equity.
Finally, in 2001, the Ontario Provincial Advisory Com-
mittee on New Predictive Genetic Technologies advised
the government to implement a moratorium on the use of
genetic information by insurance companies and to create a
special commission to make recommendations.13
These various reports did not affect the position taken
by the insurance industry in Canada. The Canadian Insti-
tute of Actuaries, the Canadian Life Insurance Medical
Officers Association and the Canadian Life and Health In-
surance Association all stated that if genetic testing oc-
curred and the results were available to the insurance ap-
plicant, insurers could request access to that information
just as it would for other aspects of the applicant’s health
history.6,14,15
In 2003, insurers, patient advocates, geneticists and re-
searchers involved in the Genetics and Society Project of
Université de Montréal, funded by Genome Canada (Que-
bec and Ontario) and in the INHERIT BRCAs Project
(Interdisciplinary Health Research International Team on
Breast Cancer Susceptibility) created the Canadian Genet-
ics and Life Insurance Task Force to debate the subject of
life insurance and genetics in Canada. The process was
both enlightening and difficult. The common aim was to
foster debate on a more equitable integration of genetic in-
formation in the underwriting process.
Our task force report (see the online appendix at www
.cmaj.ca/cgi/content/full/170/9/1421/DC2) suggests de-
bating the following 2 options:
• No use of genetic test results (excluding family history)
for a set, moderate amount of insurance coverage for a
limited period of time (5 years). This amount and time
limit could be revised if warranted.
• Creation of an independent standing body that includes
consumers, government, clinicians, industry and re-
searchers for ongoing review of criteria concerning the
reliability of genetic information for underwriting pur-
poses. This advisory body could also handle complaints
and queries from consumers.
We hope that policy-makers, insurers and physicians
will take up the challenge of this task force.
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